128 related articles for article (PubMed ID: 25567136)
1. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Kemp TJ; Hildesheim A; Weinstein SJ; Hofmann JN; Virtamo J; Albanes D; Pinto LA; Rothman N
Leukemia; 2015 Jun; 29(6):1429-31. PubMed ID: 25567136
[No Abstract] [Full Text] [Related]
2. Can serum soluble CD23 or CD30 predict the occurrence of lymphoma in HIV-infected patients?
Jarrin I; Boval B; Mazeron MC; Simoneau G; Magnier JD; Green A; Andreoli A; Bergmann JF; Sellier P
J Acquir Immune Defic Syndr; 2011 Jul; 57(3):e58-61. PubMed ID: 21860351
[No Abstract] [Full Text] [Related]
3. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma.
Schroeder JR; Saah AJ; Hoover DR; Margolick JB; Ambinder RF; Martinez-Maza O; Breen EC; Jacobson LP; Variakojis D; Rowe DT; Armenian HK
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):979-84. PubMed ID: 10566552
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Martinez-Maza O; Oken MM; Hocking W; Huang WY; Baris D; Conde B; Rothman N
Blood; 2009 Sep; 114(13):2730-2. PubMed ID: 19638620
[TBL] [Abstract][Full Text] [Related]
6. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
7. Serum sCD23 level in patients with AIDS-related non-Hodgkin's lymphoma is associated with absence of Epstein-Barr virus in tumor tissue.
Schroeder JR; Saah AJ; Ambinder RF; Martinez-Maza O; Crabb Breen E; Variakojis D; Margolick JB; Jacobson LP; Rowe DT; Hoover DR
Clin Immunol; 1999 Dec; 93(3):239-44. PubMed ID: 10600334
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD30 and CD23 in cord blood are not related to atopy in early childhood.
Oymar K; Laerdal A; Bjerknes R
Pediatr Allergy Immunol; 2000 Nov; 11(4):220-4. PubMed ID: 11110575
[TBL] [Abstract][Full Text] [Related]
9. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
10. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma.
Zinzani PL; Baccini C; Zaccaria A; Visani G; Buzzi M; Morelli A; Molinari AL; Salvucci M; Bendandi M; Rubboli D; Gherlinzoni F; Zanchini R; Tura S
Eur J Haematol; 1996 Nov; 57(5):335-40. PubMed ID: 9003473
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum level of soluble CD23 precedes development of B-non-Hodgkin's lymphoma in SIV-infected Rhesus monkeys.
Hannig H; Buske C; Mätz-Rensing K; Hunsmann G; Hiddemann W; Bodemer W
Int J Cancer; 1998 Aug; 77(5):734-40. PubMed ID: 9688307
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
[TBL] [Abstract][Full Text] [Related]
13. Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study.
Takemoto S; Iwanaga M; Sagara Y; Watanabe T
Asian Pac J Cancer Prev; 2015; 16(18):8253-8. PubMed ID: 26745069
[TBL] [Abstract][Full Text] [Related]
14. Levels of soluble CD30 in cord blood and peripheral blood during childhood are not correlated with the development of atopic disease or a family history of atopy.
Holmlund U; Bengtsson A; Nilsson C; Kusoffsky E; Lilja G; Scheynius A; Sverremark-Ekström E
Clin Exp Allergy; 2003 Nov; 33(11):1531-6. PubMed ID: 14616865
[TBL] [Abstract][Full Text] [Related]
15. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6.
Breen EC; van der Meijden M; Cumberland W; Kishimoto T; Detels R; Martínez-Maza O
Clin Immunol; 1999 Sep; 92(3):293-9. PubMed ID: 10479534
[TBL] [Abstract][Full Text] [Related]
16. The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.
Schwarzmeier JD; Shehata M; Hilgarth M; Marschitz I; Louda N; Hubmann R; Greil R
Leuk Lymphoma; 2002 Mar; 43(3):549-54. PubMed ID: 12002758
[TBL] [Abstract][Full Text] [Related]
17. Soluble cytokine receptor CD30 in atopic disorders: a case-control study.
Latza U; Davis S; Wilhelm D; McKnight B; Seyfarth M; Stein H
Clin Exp Allergy; 1999 Jan; 29(1):97-104. PubMed ID: 10051708
[TBL] [Abstract][Full Text] [Related]
18. Decrease of serum levels of soluble CD23 during immunotherapy in patients with perennial allergic rhinitis.
Tanaka A; Ohashi Y; Nakai Y
Ann Otol Rhinol Laryngol; 1999 Feb; 108(2):193-200. PubMed ID: 10030240
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
[TBL] [Abstract][Full Text] [Related]
20. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
